Prothena Corporation plc has announced that its partner Roche will advance the investigational drug prasinezumab into Phase III development for early-stage Parkinson's disease. This decision is based on data from the Phase IIb PADOVA study and ongoing open-label extensions from both the PADOVA and the Phase II PASADENA studies. Prasinezumab is an anti-alpha-synuclein antibody targeting a biological driver of Parkinson's disease progression. While the primary endpoint of time to confirmed motor progression did not achieve statistical significance, positive trends were noted, suggesting potential clinical benefits. The ongoing studies are evaluating the long-term safety and efficacy of prasinezumab in over 750 patients with early-stage Parkinson's disease. Further results from these studies will be presented as they become available.